Best Ways to Quit Smoking, Cut Your Lung Cancer Risk
Title: Best Ways to Quit Smoking, Cut Your Lung Cancer RiskCategory: Health NewsCreated: 1/5/2018 12:00:00 AMLast Editorial Review: 1/8/2018 12:00:00 AM
Authors: Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M Abstract The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 u...
Conclusions: Taken together, this work demonstrated that miR-181b might have the ability to overcome chemo resistance of small cell lung cancer cells, and restoration of this miRNA may represent a potential therapeutic strategy for improving chemo sensitivity in small cell lung cancer. PMID: 30002690 [PubMed]
We describe the methods, stakeholder engagement, and lessons learned from a study comparing the a video decision aid to standard educational materials on lung cancer screening decisions.
The concept of loose tumor tissue fragments as a pattern of invasion in lung carcinoma has recently been proposed and is included in the 2015 WHO fascicle on the classification of lung tumors, so-called ‘spread through air spaces” or STAS. This inclusion is controversial, as there are significant data to support that this histologic finding represents an artifact of tissue handling and processing rather than a pattern of invasion.
Fetal adenocarcinoma of lung is a rare, malignant pulmonary tumor, had been classified as a variant subtype of pulmonary invasive adenocarcinoma. According to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) multidisciplinary classification in 2011 and the World Health Organization (WHO) classification 2015, fetal adenocarcinoma was further classified into two subtypes, low grade (well-differentiated) and high grade fetal adenocarcinoma (HGFA) [1,2].
Lung cancer is the most common cause of cancer-related deaths in the world. Adenocarcinoma represents a histologic form of lung cancer which accounts for>60% of all cases. The need to establish non-invasive diagnostic markers in lung cancer is urgent, both in early and advanced stages, where current diagnostics rely on the result of a tissue biopsy .
Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for a majority of cases . The precise prediction of the prognosis certainly leads to the better treatment of surgically resected NSCLC cases. One candidate method for determining the prognosis of resected NSCLC is the evaluation of infiltrating macrophages in tumors, which are generally known as tumor-associated macrophages (TAMs). TAMs are a key component of the cancer microenvironment that influence tumor growth and progression [2,3].
Medical imaging is an essential component of the diagnostic procedures performed in lung cancer. Next to that, it is also used for response assessment. The imaging modalities used in oncology have evolved from simple X-rays to computed tomography (CT)- and magnetic resonance imaging (MRI) scans. Nuclear imaging has innovated by the introduction of positron-emission tomography (PET) with several tracers being 18F-fludeoxyglucose (18F-FDG) most frequently used. An 18F-FDG-PET-scan using an integrated PET-CT scanner combined with a contrast enhanced CT is nowadays a standard staging technique in thoracic oncology.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in approximately 20 –25% of lung adenocarcinomas in Western countries [1–3] and in approximately 10–15% of cases in Asia [4,5]. Considered globally, KRAS-mutant tumours constitute the most frequent potentially targetable molecular subtype of non-small-cell lung cancer (NSCLC) . As is the case with the vast maj ority of potentially actionable genetic alterations in NSCLC, KRAS mutations are almost exclusively detected in lung adenocarcinomas and are rarely found in squamous-cell cancers [7,8].
The authors regret to have noted that the data reported in Table 2 is incorrect. We have checked the reason for this, and acknowledge that a table containing wrong numbers was unfortunately submitted by us to your journal. We sincerely apologize for this grave mistake. The general results of our study as well as the conclusions as put forward in the article are, however, correct. The correct numbers are what should be in Table 2 below and are in perfect accordance to what is then shown in Figure 4.